Although several previous publications have reported the meta-analysis result of T-DM1 that involved the treatment-related adverse events, there is lack of T-DXd and they were performed with the few number of included studies or were focused on the efficacy evaluation and some certain adverse events, such as thrombocytopenia and hepatotoxicity.19, 20, 21 Current available studies are insufficient to provide the real incidences and to comprehensively understand the adverse events associated with HER2-targeted ADCs. The gene discussed is ERBB2; the disease is Thrombocytopenia.